Patented, Sustained-Release Therapeutics Delivery System Directly Through Skin
Atticus Pharma has developed a unique, patented, sustained-release system for delivering therapeutics directly through the skin. Atticus’s first product uses this topical delivery technology to administer anandamide to cutaneous lesions in lupus patients over 12-24 hours, providing the first new therapeutic for lupus lesions in 50 years. Atticus’s second product, for androgenic alopecia, will be evaluated in human subjects during 2024.
Atticus spun out of Zylö Therapeutics and was incorporated in February 2024 after Zylö secured $4M in grants and spent years developing Atticus’s technology. Since incorporation, Atticus has recruited its management team, is raising a $2 million Bridge Note as part of its $8 million series A, and it has welcomed the world’s leading authority on cutaneous lupus to its clinical advisory board.
What We’re Looking For
Atticus is seeking advisors that have experience working with pharma startups, specifically those who can advise on the fundraising process.
Financing
- A $2 million Bridge Round (convertible notes) opened in September and will remain open through November 30, 2024 with a possible extension. More than $1 million has been raised to date with half coming from the Atticus founders. Proceeds will be used to initiate IND enabling studies for the lupus program and a clinical study in human subjects for the alopecia program.
- An $8 million Series A Preferred Stock raise will follow the Bridge. Proceeds will be used to complete IND-enabling studies and to complete a Phase 1/2a clinical trial.
- Atticus will apply for several Phase 1/Phase 2 NIH grants that could bring in between $2.0 and $3.6 million. The NIH grants would be supplemental to the $8 million Convertible Bridge and Series A.
Latest News
April 17, 2024
Zylö announces the creation and spinout of Atticus Pharma Inc.
Leigh Hsu, PhD
Leigh is a biotechnology executive with 25 years’ experience in the biopharma industry. He most recently served as SVP of Business Development with CARsgen for seven years, and prior to that, he was with Lpath for six years as VP of Corporate Development & Strategy. Dr. Hsu received his PhD in molecular pathology from UC San Diego and an MBA from UC Irvine.
Scott Pancoast
Scott is CEO + Founder (2017) of Zylö Therapeutics Inc., the entity that effected the spinout of Atticus. He has served on 17 corporate boards, 4 of them publicly traded; he served as a board member for the San Diego Venture Group for six years and was Chairman for two years. Mr. Pancoast holds a BA in economics summa cum laude from UVA and an MBA with honors from Harvard Business School.
Charles E. Hinkle
Charles is an executive with 40 years’ experience as CEO and CFO of several manufacturing companies in Texas and Mexico. He grew revenue from $4 to $50 million before selling three companies to PE buyers. He also led the implementation of and certified all three companies to advanced quality control systems. Charles is a summa cum laude graduate of Washington & Lee University, a Texas CPA, and a Baker Scholar graduate of the Harvard Business School.
Dario A. Paggiarino, MD
Dario is an executive with over 35 years’ experience in clinical development of drugs and devices in multiple therapeutic areas. He has served executive roles with increasing responsibilities in companies such as Pharmacia, Pfizer, Alcon/Novartis and, over the last 10 years, at biotechnology companies such as Lpath and EyePoint Pharmaceuticals. He holds a MD degree magna cum laude from the University of La Sapienza, Rome, Italy.